Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) — shareholding pattern, promoter holding, financials and share price
About Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM)
Jagsonpal Pharmaceuticals Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as JAGSNPHARM and on the BSE under scrip code 507789. Its ISIN is INE048B01035.
Incorporated in 1978, Jagsonpal Pharmaceuticals Ltd manufactures and trades pharmaceutical products and active pharmaceutical ingredients [1]
Jagsonpal Pharmaceuticals Limited is a leading pharmaceutical company specializing in Gynaecology, Orthopaedics, and Dermatology. It operates primarily in India, holding competitive positions in these key therapeutic areas.
In FY26, the company experienced a 6% YoY revenue growth reaching ₹2,230 Mn, with an operational PAT increase of 12.5%. This demonstrates their continued profitability and resilience despite modest quarterly performance.
Listed peers in Pharmaceuticals: Hester Biosciences Ltd, Windlas Biotech Ltd, Amrutanjan Health Care Ltd, Shukra Pharmaceuticals Ltd, Fredun Pharmaceuticals Ltd, Syncom Formulations (India) Ltd.
Valuation & Returns
10 Jul 2026At ₹234.55 a share on 10 Jul 2026, Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) was valued at a price-to-earnings ratio of 35.84x against an industry P/E of 36.41x and a price-to-book of 6.44x on a book value of ₹36.45 per share as of Mar 2025. Solomo computes return on equity of 17.95% and return on capital employed of 23.5% from filed results. Earnings ratios use standalone results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 35.84x
- Industry P/E
- 36.41x
- P/B
- 6.44x
- EPS (TTM)
- ₹6.54
- Book value / share
- ₹36.45
- ROE
- 17.95%
- ROCE
- 23.5%
- ROA
- 15.48%
- Debt / equity
- 0.04x
- Dividend yield
- 1.07%
- EBITDA margin
- 23.67%
- 52-week range
- ₹154.9 – ₹301.8
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) reported revenue of ₹287 crore, net profit of ₹43 crore and earnings per share of ₹6.43. That compares with revenue of ₹269 crore and net profit of ₹55 crore in Mar 2025. Figures are standalone, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹64.2 crore and net profit ₹8.76 crore (standalone).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 218 | 237 | 209 | 269 | 287 |
| Net profit (₹ cr) | 19 | 27 | 22 | 55 | 43 |
| EPS (₹) | 2.88 | 4.08 | 3.4 | 8.34 | 6.43 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 7.16% | 11.13% | 7.29% | 28.76% |
| Profit growth | 37.01% | 47.72% | 43.19% | 146.48% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 69.05% of Jagsonpal Pharmaceuticals Ltd (JAGSNPHARM) (up 1.16 pp QoQ), foreign institutional investors (FII) hold 2.3% and domestic institutional investors (DII) hold 0.62%. Market capitalisation was ₹1,544 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2002.
Largest disclosed public shareholders in Jun 2026: MANISH GUPTA 3.08%, INVESTOR EDUCATION AND PROTECTION FUND AUTHORITY MINISTRY OF CORPORATE AFFAIRS 1.49%, AUTHUM INVESTMENT AND INFRASTRUCTURE LIMITED 1.47%, SANJIV KUMAR DUDEJA 1.41%, LINCOLN P COELHO 1.18%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 69.05% | - | 2.3% | 0.62% | 30.95% |
| Mar 2026 | 67.89% | - | 2.44% | 0.22% | 32.11% |
| Dec 2025 | 67.39% | - | 2.12% | 0.15% | 32.61% |
| Sep 2025 | 67.54% | - | 2.12% | 0.09% | 32.46% |
| Jun 2025 | 67.65% | - | 2.18% | 0.05% | 32.35% |
| Mar 2025 | 67.78% | - | 2.1% | 0% | 32.22% |
| Dec 2024 | 67.81% | - | 2.1% | 0% | 32.19% |
| Sep 2024 | 67.97% | - | 2.3% | 0.11% | 32.03% |